SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Xencor (XNCR)
XNCR 14.37+5.0%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: fitzdad55 who wrote (72)12/23/2014 12:27:23 PM
From: scaram(o)uche   of 136
 
So, yes, all of this rings a bell that's been rung many times. But I manage to forget anything that is not within focus.

:-(

I have my doubts about bispecifics of any valency, when it comes to getting an effector cell to a cancer cell, solid cancer world. And I frankly don't know if Hodgkin's is more like a leukemia or a sarcoma, when it comes to my concern. Going to read more, will let you know if I form a non-fluff opinion.

For all I know, it could already be well accepted that plenty of NK cells get to cancers of any nature, and that the problem is exclusively one of activation. Never can tell what I've missed.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News